{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:05:51Z","timestamp":1794049551804,"version":"4.8.0"},"reference-count":124,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:sec id=\"ab-jrv250033-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Approximately 27% of adults in the US and Canada report having ever used cannabis for medical purposes. An estimated 10.5% of the US population reports using cannabidiol (CBD), a chemical compound extracted from cannabis that does not have psychoactive effects, for therapeutic purposes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250033-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Conditions for which cannabinoids have approval from the US Food and Drug Administration include HIV\/AIDS\u2013related anorexia, chemotherapy-induced nausea and vomiting, and certain pediatric seizure disorders. A meta-analysis of randomized clinical trials reported a small but significant reduction in nausea and vomiting from various causes (eg, chemotherapy, cancer) when comparing prescribed cannabinoids (eg, dronabinol, nabilone) with placebo or active comparators (eg, alizapride, chlorpromazine; standardized mean difference [SMD], \u22120.29 [95% CI, \u22120.39 to  \u22120.18]). A meta-analysis of randomized clinical trials among patients with HIV\/AIDS reported that cannabinoids had a moderate effect on increasing body weight compared with placebo (SMD, 0.57 [95% CI, 0.22 to 0.92]). Evidence-based guidelines do not recommend the use of inhaled or high-potency cannabis (\u226510% or 10 mg \u03949-tetrahydrocannabinol [\u03949-THC]) for medical purposes. High-potency cannabis compared with low-potency cannabis use is associated with increased risk of psychotic symptoms (12.4% vs 7.1%) and generalized anxiety disorder (19.1% vs 11.6%). A meta-analysis of observational studies reported that 29% of individuals who used cannabis for medical purposes met criteria for cannabis use disorder. Daily inhaled cannabis use compared with nondaily use was associated with an increased risk of coronary heart disease (2.0% vs 0.9%), myocardial infarction (1.7% vs 1.3%), and stroke (2.6% vs 1.0%). Evidence from randomized clinical trials does not support the use of cannabis or cannabinoids for most conditions for which it is promoted, such as acute pain and insomnia. Before considering cannabis or cannabinoids for medical use, clinicians should consult applicable institutional, state, and national regulations; evaluate for drug-drug interactions; and assess for contraindications (eg, pregnancy) or conditions in which risks likely outweigh benefits (eg, schizophrenia or ischemic heart disease). For patients using cannabis or cannabinoids for treatment of medical conditions, clinicians should discuss harm reduction strategies, including avoiding concurrent use with alcohol or other central nervous system depressants such as benzodiazepines, using the lowest effective dose, and avoiding use when driving or operating machinery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250033-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Evidence is insufficient for the use of cannabis or cannabinoids for most medical indications. Clear guidance from clinicians is essential to support safe, evidence-based decision-making. Clinicians should weigh benefits against risks when engaging patients in informed discussions about cannabis or cannabinoid use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.19433","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:31:25Z","timestamp":1764174685000},"page":"345","source":"Crossref","is-referenced-by-count":74,"title":["Therapeutic Use of Cannabis and Cannabinoids"],"prefix":"10.1001","volume":"335","author":[{"given":"Michael","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, California"},{"name":"Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Jordan","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Population Health, NYU Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Hill","sequence":"additional","affiliation":[{"name":"Division of Addiction Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"jrv250033r1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230167","article-title":"Mapping cannabis potency in medical and recreational programs in the United States.","volume":"15","author":"Cash","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"jrv250033r2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S2215-0366(22)00161-4","article-title":"Association of cannabis potency with mental ill health and addiction: a systematic review.","volume":"9","author":"Petrilli","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"jrv250033r3","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/jamapsychiatry.2020.1035","article-title":"Association of high-potency cannabis use with mental health and substance use in adolescence.","volume":"77","author":"Hines","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"15","key":"jrv250033r5","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1111\/bph.15865","article-title":"Review of delta-8-tetrahydrocannabinol (?8-THC): comparative pharmacology with ?9-THC.","volume":"179","author":"Tagen","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"9","key":"jrv250033r6","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/ejp.2016","article-title":"Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy.","volume":"26","author":"Sepulveda","year":"2022","journal-title":"Eur J Pain"},{"issue":"5","key":"jrv250033r7","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00213-021-06047-8","article-title":"Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada.","volume":"239","author":"Leung","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"jrv250033r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2025.102985","article-title":"Patterns of cannabidiol use among marijuana users in the United States.","volume":"50","author":"Park","year":"2025","journal-title":"Prev Med Rep"},{"issue":"1","key":"jrv250033r9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s42238-021-00100-1","article-title":"A systematic review of medical students\u2019 and professionals\u2019 attitudes and knowledge regarding medical cannabis.","volume":"3","author":"Weisman","year":"2021","journal-title":"J Cannabis Res"},{"issue":"1","key":"jrv250033r10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12875-022-01651-9","article-title":"Medical marijuana knowledge and attitudes amongst internal medicine residents.","volume":"23","author":"Makki","year":"2022","journal-title":"BMC Prim Care"},{"issue":"1","key":"jrv250033r11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12875-021-01559-w","article-title":"Physicians\u2019 experiences, attitudes, and beliefs towards medical cannabis: a systematic literature review.","volume":"22","author":"R\u00f8nne","year":"2021","journal-title":"BMC Fam Pract"},{"issue":"10","key":"jrv250033r12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jama.2019.11868","article-title":"Medical use of cannabis in 2019.","volume":"322","author":"Hill","year":"2019","journal-title":"JAMA"},{"key":"jrv250033r13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fncel.2016.00294","article-title":"Cannabinoid receptors in the central nervous system: their signaling and roles in disease.","volume":"10","author":"Kendall","year":"2017","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"jrv250033r14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","article-title":"Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.","volume":"15","author":"Pacher","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"jrv250033r15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm1561","article-title":"Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells.","volume":"13","author":"Maresz","year":"2007","journal-title":"Nat Med"},{"issue":"1","key":"jrv250033r16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000531058","article-title":"Pronounced state-level disparities in prescription of cannabinoids to Medicaid patients.","volume":"6","author":"Liu","year":"2023","journal-title":"Med Cannabis Cannabinoids"},{"issue":"1","key":"jrv250033r17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12916-022-02459-1","article-title":"Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.","volume":"20","author":"Bilbao","year":"2022","journal-title":"BMC Med"},{"issue":"4","key":"jrv250033r21","doi-asserted-by":"publisher","DOI":"10.1177\/20552173241282379","article-title":"Cannabinoids for spasticity in patients with multiple sclerosis: a systematic review and meta-analysis.","volume":"10","author":"Azadvari","year":"2024","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"7","key":"jrv250033r22","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14737175.2021.1935879","article-title":"Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years\u2019 accumulated evidence from clinical trials.","volume":"21","author":"Prieto Gonz\u00e1lez","year":"2021","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"jrv250033r23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/can.2019.0078","article-title":"An analysis of over-the-counter cannabidiol products in the United Kingdom.","volume":"7","author":"Liebling","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"issue":"7","key":"jrv250033r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4841","article-title":"Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial.","volume":"1","author":"Spindle","year":"2018","journal-title":"JAMA Netw Open"},{"key":"jrv250033r26","first-page":"1","article-title":"Mechanisms of action and pharmacokinetics of cannabis.","volume":"25","author":"Chayasirisobhon","year":"2020","journal-title":"Perm J"},{"key":"jrv250033r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107969","article-title":"Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis.","volume":"211","author":"Schlienz","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"jrv250033r28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jat\/bkx012","article-title":"Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes.","volume":"41","author":"Vandrey","year":"2017","journal-title":"J Anal Toxicol"},{"issue":"8","key":"jrv250033r29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.7326\/M18-2809","article-title":"Acute illness associated with cannabis use, by route of exposure: an observational study.","volume":"170","author":"Monte","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"jrv250033r30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jat\/bkae001","article-title":"Pharmacokinetics and pharmacodynamics of five distinct commercially available hemp-derived topical cannabidiol products.","volume":"48","author":"Zamarripa","year":"2024","journal-title":"J Anal Toxicol"},{"issue":"5","key":"jrv250033r31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.7326\/ANNALS-24-03319","article-title":"Cannabis or cannabinoids for the management of chronic noncancer pain: best practice advice from the American College of Physicians.","volume":"178","author":"Kansagara","year":"2025","journal-title":"Ann Intern Med"},{"issue":"6","key":"jrv250033r32","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1176\/appi.ajp.2015.15070907","article-title":"Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the national epidemiologic survey on alcohol and related conditions-III.","volume":"173","author":"Hasin","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"10","key":"jrv250033r35","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1161\/CIR.0000000000000883","article-title":"Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association.","volume":"142","author":"Page","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"jrv250033r36","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3899\/jrheum.181120","article-title":"Position statement: a pragmatic approach for medical cannabis and patients with rheumatic diseases.","volume":"46","author":"Fitzcharles","year":"2019","journal-title":"J Rheumatol"},{"issue":"6","key":"jrv250033r39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.pedhc.2019.07.010","article-title":"Medical marijuana guidelines for practice: health policy implications.","volume":"33","author":"Russell","year":"2019","journal-title":"J Pediatr Health Care"},{"issue":"1","key":"jrv250033r41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5770\/cgj.23.424","article-title":"Canadian guidelines on cannabis use disorder among older adults.","volume":"23","author":"Bertram","year":"2020","journal-title":"Can Geriatr J"},{"issue":"2","key":"jrv250033r43","first-page":"111","article-title":"Simplified guideline for prescribing medical cannabinoids in primary care.","volume":"64","author":"Allan","year":"2018","journal-title":"Can Fam Physician"},{"issue":"1","key":"jrv250033r44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/2193-1801-2-236","article-title":"A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC\/CBD oromucosal spray in healthy volunteers.","volume":"2","author":"Stott","year":"2013","journal-title":"Springerplus"},{"issue":"5","key":"jrv250033r45","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13812","article-title":"Evaluation of potential drug-drug interactions with medical cannabis.","volume":"17","author":"Ho","year":"2024","journal-title":"Clin Transl Sci"},{"key":"jrv250033r46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1282831","article-title":"Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis.","volume":"15","author":"Nachnani","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"jrv250033r47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.psc.2022.05.002","article-title":"Policy ahead of the science: medical cannabis laws versus scientific evidence.","volume":"45","author":"Burnett","year":"2022","journal-title":"Psychiatr Clin North Am"},{"issue":"6","key":"jrv250033r48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.14809","article-title":"Cannabis use reported by patients receiving primary care in a large health system.","volume":"7","author":"Gelberg","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"13","key":"jrv250033r49","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/JCO.23.02596","article-title":"Cannabis and cannabinoids in adults with cancer: ASCO guideline.","volume":"42","author":"Braun","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv250033r50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00520-025-09251-w","article-title":"Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting\u2014a systematic review and meta-analysis.","volume":"33","author":"Chow","year":"2025","journal-title":"Support Care Cancer"},{"key":"jrv250033r51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/HIV.S81420","article-title":"Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS.","volume":"8","author":"Badowski","year":"2016","journal-title":"HIV AIDS (Auckl)"},{"key":"jrv250033r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy\u2014a systematic literature review and network meta-analysis.","volume":"48","author":"Kanters","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"24","key":"jrv250033r53","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis.","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"jrv250033r54","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/jcsm.12273","article-title":"Systematic review and meta-analysis of cannabinoids in palliative medicine.","volume":"9","author":"M\u00fccke","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"jrv250033r57","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251313914","article-title":"The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis.","volume":"18","author":"Ong","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"jrv250033r58","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/j.pain.0000000000002265","article-title":"International association for the study of pain presidential task force on cannabis and cannabinoid analgesia position statement.","volume":"162","author":"IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia","year":"2021","journal-title":"Pain"},{"issue":"8","key":"jrv250033r60","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/pmrj.13211","article-title":"AAPM&R consensus guidance on spasticity assessment and management.","volume":"16","author":"Verduzco-Gutierrez","year":"2024","journal-title":"PM R"},{"issue":"11","key":"jrv250033r62","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1136\/jnnp-2012-302468","article-title":"Multiple sclerosis and extract of cannabis: results of the MUSEC trial.","volume":"83","author":"Zajicek","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9395","key":"jrv250033r63","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"jrv250033r64","article-title":"Cannabis-based medicines and medical cannabis for adults with cancer pain.","volume":"6","author":"H\u00e4user","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"jrv250033r65","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.sleep.2021.01.023","article-title":"Endorsement of European guideline for the diagnosis and treatment of insomnia by the World Sleep Society.","volume":"81","author":"Morin","year":"2021","journal-title":"Sleep Med"},{"issue":"2","key":"jrv250033r67","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab234","article-title":"Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials.","volume":"45","author":"AminiLari","year":"2022","journal-title":"Sleep"},{"issue":"9","key":"jrv250033r68","article-title":"Cannabinoids for the treatment of dementia.","volume":"9","author":"Bosnjak Kuharic","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"jrv250033r70","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1176\/appi.ajp.2021.21030320","article-title":"Risks and benefits of cannabis and cannabinoids in psychiatry.","volume":"179","author":"Hill","year":"2022","journal-title":"Am J Psychiatry"},{"issue":"2","key":"jrv250033r71","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4103\/ipj.ipj_43_23","article-title":"Cannabis use and its relationship with bipolar disorder: a systematic review and meta-analysis.","volume":"32","author":"Maggu","year":"2023","journal-title":"Ind Psychiatry J"},{"issue":"5","key":"jrv250033r72","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","article-title":"Meta-analysis of the association between the level of cannabis use and risk of psychosis.","volume":"42","author":"Marconi","year":"2016","journal-title":"Schizophr Bull"},{"issue":"5","key":"jrv250033r73","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/mp.2016.252","article-title":"Cannabis use and risk of schizophrenia: a Mendelian randomization study.","volume":"23","author":"Vaucher","year":"2018","journal-title":"Mol Psychiatry"},{"key":"jrv250033r74","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1346207","article-title":"Cannabis use and mood disorders: a systematic review.","volume":"12","author":"Sorkhou","year":"2024","journal-title":"Front Public Health"},{"issue":"1","key":"jrv250033r75","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/19585969.2023.2231466","article-title":"Suicidality risk after using cannabis and cannabinoids: an umbrella review.","volume":"25","author":"Shamabadi","year":"2023","journal-title":"Dialogues Clin Neurosci"},{"issue":"3","key":"jrv250033r77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246990","article-title":"The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial.","volume":"16","author":"Bonn-Miller","year":"2021","journal-title":"PLoS One"},{"key":"jrv250033r78","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116049","article-title":"Therapeutic potential of cannabidiol (CBD) in anxiety disorders: a systematic review and meta-analysis.","volume":"339","author":"Han","year":"2024","journal-title":"Psychiatry Res"},{"issue":"4","key":"jrv250033r79","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.","volume":"39","author":"Zuardi","year":"2006","journal-title":"Braz J Med Biol Res"},{"issue":"4","key":"jrv250033r80","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1089\/can.2019.0079","article-title":"Cannabinoids in the management of acute pain: a systematic review and meta-analysis.","volume":"5","author":"Gazendam","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"issue":"S1","key":"jrv250033r81","doi-asserted-by":"publisher","first-page":"320S","DOI":"10.1002\/j.1552-4604.1981.tb02610.x","article-title":"Evaluation of intramuscular levonantradol and placebo in acute postoperative pain.","volume":"21","author":"Jain","year":"1981","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"jrv250033r82","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41386-022-01322-4","article-title":"Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies.","volume":"47","author":"Nielsen","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"jrv250033r83","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JPD-212923","article-title":"Effects of cannabis in Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"12","author":"Urbi","year":"2022","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"jrv250033r85","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0161-6420(80)35258-5","article-title":"Effect of marihuana on intraocular and blood pressure in glaucoma.","volume":"87","author":"Merritt","year":"1980","journal-title":"Ophthalmology"},{"issue":"6","key":"jrv250033r86","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/dmcn.14165","article-title":"Cannabinoids for the treatment of spasticity.","volume":"61","author":"Nielsen","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"jrv250033r87","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/jcag\/gwy064","article-title":"Canadian Association of Gastroenterology position statement: use of cannabis in gastroenterological and hepatic disorders.","volume":"2","author":"Andrews","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"issue":"2","key":"jrv250033r88","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/ibd\/izae158","article-title":"Meta-analysis of the therapeutic impact of cannabinoids in inflammatory bowel disease.","volume":"31","author":"Kang","year":"2025","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"jrv250033r89","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45653","article-title":"Birth outcomes of neonates exposed to marijuana in utero: a systematic review and meta-analysis.","volume":"5","author":"Marchand","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"jrv250033r90","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1373\/clinchem.2012.194381","article-title":"Cannabis effects on driving skills.","volume":"59","author":"Hartman","year":"2013","journal-title":"Clin Chem"},{"key":"jrv250033r91","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104832","article-title":"Cannabis consumption and motor vehicle collision: a systematic review and meta-analysis of observational studies.","volume":"142","author":"Jin","year":"2025","journal-title":"Int J Drug Policy"},{"key":"jrv250033r92","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2023.107740","article-title":"High potency cannabis use, mental health symptoms and cannabis dependence: triangulating the evidence.","volume":"144","author":"Petrilli","year":"2023","journal-title":"Addict Behav"},{"issue":"14","key":"jrv250033r93","doi-asserted-by":"publisher","first-page":"E694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ"},{"issue":"6","key":"jrv250033r95","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamapsychiatry.2018.0335","article-title":"Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis.","volume":"75","author":"Scott","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"jrv250033r96","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.neubiorev.2019.10.014","article-title":"Neurocognitive consequences of chronic cannabis use: a systematic review and meta-analysis.","volume":"108","author":"Figueiredo","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"jrv250033r97","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/a0029117","article-title":"Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis.","volume":"20","author":"Schreiner","year":"2012","journal-title":"Exp Clin Psychopharmacol"},{"issue":"5","key":"jrv250033r98","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030178","article-title":"Association of cannabis use with cardiovascular outcomes among US adults.","volume":"13","author":"Jeffers","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"jrv250033r99","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30189","article-title":"Assessment of nicotine and cannabis vaping and respiratory symptoms in young adults.","volume":"3","author":"Braymiller","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"jrv250033r100","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bcpt.12962","article-title":"The prevalence of cannabinoid hyperemesis syndrome among regular marijuana smokers in an urban public hospital.","volume":"122","author":"Habboushe","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"jrv250033r101","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1053\/j.gastro.2024.01.040","article-title":"AGA clinical practice update on diagnosis and management of cannabinoid hyperemesis syndrome.","volume":"166","author":"Rubio-Tapia","year":"2024","journal-title":"Gastroenterology"},{"issue":"4","key":"jrv250033r102","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2370","article-title":"Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: a systematic review and meta-analysis.","volume":"3","author":"Bahji","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7","key":"jrv250033r103","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/add.15743","article-title":"Clinical management of cannabis withdrawal.","volume":"117","author":"Connor","year":"2022","journal-title":"Addiction"},{"key":"jrv250033r104","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111263","article-title":"The prevalence of cannabis use disorders in people who use medicinal cannabis: a systematic review and meta-analysis.","volume":"257","author":"Dawson","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"jrv250033r105","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2024-325429","article-title":"Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis.","author":"Storck","year":"2025","journal-title":"Heart"},{"issue":"5","key":"jrv250033r106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101698","article-title":"Myocardial infarction and cardiovascular risks associated with cannabis use: a multicenter retrospective study.","volume":"4","author":"Kamel","year":"2025","journal-title":"JACC Adv"},{"issue":"10","key":"jrv250033r107","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1093\/cvr\/cvab264","article-title":"Risk factors profile of young and older patients with myocardial infarction.","volume":"118","author":"Sagris","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"23","key":"jrv250033r108","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.037731","article-title":"Acute effects of cannabis inhalation on arterial stiffness, vascular endothelial function, and cardiac function.","volume":"13","author":"Cheung","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"jrv250033r109","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamacardio.2025.1399","article-title":"Association of endothelial dysfunction with chronic marijuana smoking and THC-edible use.","volume":"10","author":"Mohammadi","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"1","key":"jrv250033r111","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52362","article-title":"Neurocognitive impact of exposure to cannabis concentrates and cannabinoids including vaping in children and adolescents: a systematic review.","volume":"16","author":"Saavedra","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"jrv250033r112","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12890-025-03516-0","article-title":"Cannabis consumption and risk of asthma: a systematic review and meta-analysis.","volume":"25","author":"Malvi","year":"2025","journal-title":"BMC Pulm Med"},{"issue":"2","key":"jrv250033r113","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7326\/M18-0522","article-title":"Marijuana use, respiratory symptoms, and pulmonary function: a systematic review and meta-analysis.","volume":"169","author":"Ghasemiesfe","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"jrv250033r114","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1001\/jamaneurol.2025.0530","article-title":"Risk of dementia in individuals with emergency department visits or hospitalizations due to cannabis.","volume":"82","author":"Myran","year":"2025","journal-title":"JAMA Neurol"},{"issue":"17","key":"jrv250033r115","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online.","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"jrv250033r116","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s42238-023-00200-0","article-title":"High levels of pesticides found in illicit cannabis inflorescence compared to licensed samples in Canadian study using expanded 327 pesticides multiresidue method.","volume":"5","author":"Gagnon","year":"2023","journal-title":"J Cannabis Res"},{"issue":"pt 1","key":"jrv250033r117","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2022.158110","article-title":"Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products.","volume":"851","author":"Gardener","year":"2022","journal-title":"Sci Total Environ"},{"issue":"5","key":"jrv250033r118","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38523","article-title":"A rare case of diffuse alveolar hemorrhage caused by fentanyl-laced marijuana.","volume":"15","author":"Le","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"jrv250033r119","doi-asserted-by":"publisher","first-page":"20822","DOI":"10.1038\/s41598-025-03854-3","article-title":"Accuracy of labeled THC potency across flower and concentrate cannabis products.","volume":"15","author":"Giordano","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"jrv250033r120","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s42238-024-00220-4","article-title":"Evaluation of dispensaries\u2019 cannabis flowers for accuracy of labeling of cannabinoids content.","volume":"6","author":"Geweda","year":"2024","journal-title":"J Cannabis Res"},{"key":"jrv250033r121","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1335441","article-title":"Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples.","volume":"15","author":"Gidal","year":"2024","journal-title":"Front Pharmacol"},{"issue":"12","key":"jrv250033r122","doi-asserted-by":"publisher","first-page":"7499","DOI":"10.3390\/ijerph19127499","article-title":"Perceived stigma of patients undergoing treatment with cannabis-based medicinal products.","volume":"19","author":"Troup","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"jrv250033r123","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jpain.2010.02.008","article-title":"Approaches to improve pain relief while minimizing opioid abuse liability.","volume":"11","author":"Webster","year":"2010","journal-title":"J Pain"},{"issue":"12","key":"jrv250033r124","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/AJP.0000000000000145","article-title":"The medicinal cannabis treatment agreement: providing information to chronic pain patients via a written document.","volume":"31","author":"Wilsey","year":"2015","journal-title":"Clin J Pain"},{"key":"jrv250033r24","doi-asserted-by":"crossref","DOI":"10.17226\/27766","volume-title":"Cannabis Policy Impacts Public Health and Health Equity","author":"Teutsch","year":"2024"},{"key":"jrv250033r94","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"jrv250033r4","unstructured":"7 Things you need to know about edible cannabis. Canadian Centre on Substance Use and Addiction; 2019. Accessed June 30, 2025. https:\/\/www.ccsa.ca\/sites\/default\/files\/2019-06\/CCSA-7-Things-About-Edible-Cannabis-2019-en.pdf"},{"key":"jrv250033r18","unstructured":"Epidiolex (cannabidiol). Package insert. Jazz Pharmaceutical. 2018. Accessed August 15, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf"},{"key":"jrv250033r19","unstructured":"Dronabinol. Package insert. AbbVie  Accessed August 15, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/018651s033lbl.pdf"},{"key":"jrv250033r20","unstructured":"US Food and Drug Administration (FDA). Nabilone. Package insert. Published online 2006. Accessed August 15, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/018677s011lbl.pdf"},{"key":"jrv250033r33","unstructured":"Guidance in Authorizing Cannabis Products Within Primary Care. The College of Family Physicians of Canada; March 2021. Accessed August 15, 2025. https:\/\/www.cfpc.ca\/CFPC\/media\/PDF\/CFPC-Guidance-in-Cannabis-Within-Primary-Care.pdf"},{"key":"jrv250033r34","unstructured":"Public Policy Statement on Cannabis. American Society of Addiction Medicine; 2020. Accessed August 15, 2025. https:\/\/downloads.asam.org\/sitefinity-production-blobs\/docs\/default-source\/public-policy-statements\/2020-public-policy-statement-on-cannabis---reaffirmed-thru-12-12-30.pdf?sfvrsn=6e63f8ca_2"},{"key":"jrv250033r37","unstructured":"Sativex. GW Pharmaceuticals Ltd; 2023. March 30, 2012. Accessed August 15, 2025. https:\/\/pdf.hres.ca\/dpd_pm\/00016162.PDF"},{"key":"jrv250033r38","unstructured":"Information for health care professionals: cannabis (marihuana, marijuana) and the cannabinoids. Government of Canada. 2018. Accessed July 11, 2025. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/information-medical-practitioners\/information-health-care-professionals-cannabis-cannabinoids.html"},{"key":"jrv250033r40","unstructured":"Position statement on impact of cannabis on children and adolescents. American Psychiatric Association. 2020. Accessed July 25, 2025. https:\/\/johnnysambassadors.org\/wp-content\/uploads\/2022\/01\/Position-Cannabis-Impact-Children-Adolescents.pdf"},{"key":"jrv250033r42","unstructured":"A guide to cannabis for older adults. Canadian Centre on Substance Use and Addiction. 2020. Accessed September 1, 2025. https:\/\/www.ccsa.ca\/sites\/default\/files\/2020-07\/CCSA-Cannabis-Use-Older-Adults-Guide-2020-en.pdf"},{"key":"jrv250033r55","unstructured":"AES position statement on cannabis as a treatment for patients with epileptic seizures. American Epilepsy Society. September 16, 2022. Accessed July 25, 2025. https:\/\/aesnet.org\/about\/about-aes\/position-statements\/aes-position-statement-on-cannabis-as-a-treatment-for-patients-with-epileptic-seizures"},{"key":"jrv250033r56","unstructured":"AAN position. Use of medical cannabis for neurologic disorders. American Academy of Neurology; 2020. Accessed July 25, 2025. https:\/\/www.aan.com\/advocacy\/medical-cannabis-position-statement"},{"key":"jrv250033r59","unstructured":"Living systematic review on cannabis and other plant-based treatments for chronic pain. Agency for Healthcare Research and Quality. August 4, 2024. Accessed July 5, 2025. https:\/\/effectivehealthcare.ahrq.gov\/products\/plant-based-chronic-pain-treatment\/living-review"},{"key":"jrv250033r61","unstructured":"Sativex for moderate to severe spasticity in multiple sclerosis (MS)-prescribing guideline in primary care. National Health Service Accessed October 6, 2025.  https:\/\/nclhealthandcare.org.uk\/wp-content\/uploads\/2023\/09\/SCG_Sativex.pdf"},{"key":"jrv250033r66","unstructured":"Insomnia guideline. Kaiser Permanente. 2021. Accessed July 5, 2025. https:\/\/wa-provider.kaiserpermanente.org\/static\/pdf\/"},{"key":"jrv250033r69","unstructured":"Position statement in opposition to cannabis as medicine. American Psychiatric Association. 2019. Accessed August 15, 2025. https:\/\/www.psychiatry.org\/getattachment\/12aa44f8-016e-4f8c-8b92-d3fb11a7155f\/Position-Cannabis-as-Medicine.pdf"},{"key":"jrv250033r76","unstructured":"VA\/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. US Department of Veterans Affairs. 2023. Accessed August 15, 2025. https:\/\/www.healthquality.va.gov\/guidelines\/MH\/ptsd\/VA-DoD-CPG-PTSD-Full-CPG-Edited-111624-V5-81825.pdf"},{"key":"jrv250033r84","unstructured":"Turbert? D, Gudgel? D. Does marijuana help treat glaucoma or other eye conditions? American Academy of Ophthalmology. December 13, 2023. Accessed July 2, 2025. https:\/\/www.aao.org\/eye-health\/tips-prevention\/medical-marijuana-glaucoma-treament"},{"key":"jrv250033r110","unstructured":"Therapeutic Effects of cannabis and cannabinoids. In: The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press; 2017. Accessed July 2, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK425767\/"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2842072\/jama_hsu_2025_rv_250033_1768590537.33161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:00:28Z","timestamp":1769529628000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2842072"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.19433","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}